Skip to main content
ACHIEVE LIFE SCIENCES, INC. logo

ACHIEVE LIFE SCIENCES, INC. — Investor Relations & Filings

Ticker · ACHV ISIN · US0044685008 LEI · 549300V82ZKZDTAU0A46 US Manufacturing
Open in API
Filings indexed 1,014 across all filing types
Latest filing 2009-07-20 Regulatory Filings
Country US United States of America
Listing US ACHV

About ACHIEVE LIFE SCIENCES, INC.

https://achievelifesciences.com/

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's primary focus is the development and commercialization of its lead product candidate, cytisinicline, for smoking cessation. Following the successful completion of two Phase 3 studies, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which has been accepted for review. If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for nicotine dependence in the United States in nearly two decades.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings
2009-07-20 English
Regulatory Filings 2009
Regulatory Filings Classification · 100% confidence The document is a letter from OncoGenex Pharmaceuticals to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a regulatory filing process, specifically about the effectiveness of a registration statement for securities. The document is short (2040 characters) and does not contain any financial data, report content, or detailed disclosures. It is not a financial report, earnings release, or any form of annual or interim report. It is also not a proxy, voting result, or management change announcement. The content fits the category of a Regulatory Filing (RNS), which includes correspondence, compliance documents, and other filings that do not fit into more specific categories.
2009-07-15 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from OncoGenex Pharmaceuticals to the SEC regarding a Registration Statement on Form S-3. It discusses amendments to the Form S-3 and incorporation of a Form 8-K. The content is a regulatory correspondence related to securities registration and compliance, not a financial report, earnings release, or other specific report types. The document length is short (2017 characters) and is clearly a letter responding to SEC comments, which fits the category of Regulatory Filings (RNS) as a fallback for miscellaneous regulatory communications that do not fit other categories.
2009-07-13 English
AMENDMENT NO. 1 TO FORM S-3
Capital/Financing Update Classification · 100% confidence The document is titled 'Amendment No. 1 to Form S-3' and is a registration statement filed with the SEC under the Securities Act of 1933. It is a shelf registration statement allowing the company to offer and sell securities up to $100 million. The document includes a prospectus describing the securities to be offered, risk factors, company overview, and other related information. This type of filing is related to capital raising activities and financing. It is not an earnings release, annual report, or other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, confirming it is not merely an announcement but the actual registration statement amendment.
2009-07-13 English
FORM 4 SUBMISSION
Director's Dealing
2009-07-10 English
Regulatory Filings 2009
Regulatory Filings
2009-07-09 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.